1. Home
  2. TRDA vs UIS Comparison

TRDA vs UIS Comparison

Compare TRDA & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$7.08

Market Cap

274.5M

Sector

Health Care

ML Signal

HOLD

Logo Unisys Corporation New

UIS

Unisys Corporation New

HOLD

Current Price

$4.52

Market Cap

220.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
UIS
Founded
2016
1942
Country
United States
United States
Employees
152
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
274.5M
220.2M
IPO Year
2021
1994

Fundamental Metrics

Financial Performance
Metric
TRDA
UIS
Price
$7.08
$4.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$21.00
$5.67
AVG Volume (30 Days)
677.8K
883.0K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,421,000.00
$1,950,100,000.00
Revenue This Year
$39.97
N/A
Revenue Next Year
$50.80
$2.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$1.97
52 Week High
$16.45
$5.07

Technical Indicators

Market Signals
Indicator
TRDA
UIS
Relative Strength Index (RSI) 37.64 83.35
Support Level $5.75 $2.59
Resistance Level $7.54 N/A
Average True Range (ATR) 0.50 0.25
MACD 0.10 0.12
Stochastic Oscillator 76.46 98.58

Price Performance

Historical Comparison
TRDA
UIS

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.

Share on Social Networks: